CrossAssetDataThe Company File
···
CRON

Cronos Group Inc.

Cronos Group Inc. is classed by the SEC under Medicinal Chemicals & Botanical Products (industry code 2833), based in Stayner, ON. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $147 million and a loss of $9 million (its filed statements).

Product business Medicinal Chemicals & Botanical Products Stayner, ON filings since 2015 9 of 9 filed
Ask the desk about CRON → Compare CRON with USNA → Price chart on TradingView ↗ Full EDGAR file ↗ Watch CRON →

Sector peers: USNATLRYTRLVDFTX

6.3/10headline grade
vs its business-model standard
5.9/10past 6.8/10present 6.3/10future

Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a product business: prior from its industry code (SEC 2833, Medicinal Chemicals & Botanical Products); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.

The grade, in three tenses

Headline 6.3 out of ten, 9 of 9 metrics filed: past 5.9 out of ten, present 6.8 out of ten, future 6.3 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.

The nine metrics

  • Surviving crises (past): 1.8 out of ten. 7 warning events since 2017; the latest 2024-04-17. 18th percentile among 20 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Track record (past): 7.8 out of ten. +61.6% a year over 9 filed years; profitable in 2 of 9. 78th percentile among 18 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Shareholder treatment (past): 7.9 out of ten. Share count grew 0.6% a year. 100% of cash flow returned. Insiders: 0 sales, 0 purchases. 79th percentile among 9 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Financial health (present): 6.9 out of ten. ROE -1%: lost 1¢ per shareholder dollar. Leverage 5%: owes 5¢ per asset dollar. 69th percentile among 20 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Industry position (present): 6.7 out of ten. top 33% of 18 in its family; net margin -6.4%. 67th percentile among 18 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Leadership (present): 6.7 out of ten. top 33% of 12 in its family for leadership; chief executive since 2022. 67th percentile among 12 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
  • Room to expand (future): 6.7 out of ten. top 33% of 18 in its family for room to expand. 67th percentile among 18 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Growth drivers (future): 5.2 out of ten. top 48% of 18 in its family for growth drivers. 52nd percentile among 18 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Expectations vs reality (future): 6.9 out of ten. top 31% of 18 in its family for expectations against reality. 69th percentile among 18 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).

The filing record

Newest annual report: Form 10-K filed 2026-02-26 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-08-06 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-08-06 (on EDGAR). Newest filing: Form 8-K, 2026-09-11. Filings on record since 2015. Read from EDGAR 2026-10-12.

Where the revenue comes from

Product and service lines in fiscal 2025: Cannabis Flower 74%, Cannabis Extracts 26%, Product and Service Other under 1%. By geography: Canada 62%, Israel 28%, Other countries 10%. As tagged in its annual report (Form 10-K, filed 2026-02-26).

Who runs it

Gorenstein, Michael Ryan (Chairman, Chief Executive Officer, and President); Buggy, Shannon (Senior Vice President, Global Head of People); Kenost, Jared Matthew (Vice President, Controller); Weigensberg, Arye (Senior Vice President, Head of Research and Development); Shlimak, Anna (Chief Financial Officer); Jacobson, Jeffrey David (Chief Growth Officer); Doucet, Terrence Gregory Joseph (General Counsel and Corporate Secretary); Wagner, Adam (General Manager, Cronos Israel); Wilson, Lloyd Anderson (VP, Controller); Adler, Jason Marc (director); and 3 more. 13 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.

This file: Overview · Past · Present · Future · Filings · every company on file

Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.